Cadrenal Therapeutics, Inc. highlighted a key opinion leader presentation at the November 2024 European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit on November 12, 2024. The presentation featured tecarfarin historical data and Cadrenal's proposed clinical trial protocol.
Dr. Mandeep R. Mehra delivered the presentation, titled Tecarfarin and Hemocompatibility with LVAD Therapy (TECH-LVAD), outlining the proposed clinical trial protocol recently submitted to the U.S. Food and Drug Administration (FDA). The trial aims to evaluate tecarfarin versus warfarin in patients with the Abbott HeartMate3 (HM3) left ventricular assist device (LVAD).
Dr. Mehra highlighted data from past trials demonstrating an inverse relationship between bleeding rates and time in therapeutic range (TTR) for HM3 patients, and evidence indicating tecarfarin's potential to improve TTR. He also noted that tecarfarin's exposure is not altered by end-stage kidney disease (ESKD), unlike warfarin, which is a critical differentiator for LVAD patients often having kidney impairment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.